The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AbbVie; Amgen; Astellas Pharma; Janssen; Novartis; Pfizer
A phase 1b study of blinatumomab with the anti-programmed cell death (PD)-1 antibody AMG 404 in adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).
 
Cristina Papayannidis
No Relationships to Disclose
 
Erika Borlenghi
No Relationships to Disclose
 
David Yeung
Honoraria - Amgen; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis
 
Sigrid Machherndl-Spandl
Honoraria - AbbVie; Bristol-Myers Squibb; Celgene; Pfizer
 
Mar Bellido
Research Funding - Amgen; Janssen
 
Karamjeet Sandhu
No Relationships to Disclose
 
Hansen Wong
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Erik Rasmussen
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Gerhard Zugmaier
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Patents, Royalties, Other Intellectual Property - Multiple patents
 
Ana Markovic
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Paul R. Gordon
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda